PEDIATRICS Vol. 95 No. 1 January 1995, pp. 9-10
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilimas, J. A.
Right arrow Articles by Crist, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilimas, J. A.
Right arrow Articles by Crist, W. M.

Erythropoietin—Not Yet a Standard Treatment for Anemia of Prematurity

Judith A. Wilimas MD1 and William M. Crist MD1

1 Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101-0318

In this issue of Pediatrics, Shannon and coworkers report that the frequency and volume of red cell transfusions administered to premature infants can be decreased by using recombinant human erythropoietin (r-HuEPO). We believe that the most important contribution of this study may relate as much to its design—that is, the application of clearly defined transfusion guidelines—as to the efficacy of r-HuEPO in this setting.

In this randomized, controlled multicenter trial, 157 infants weighing <1250 g at birth received either r-HuEPO or placebo. These infants (mean age = 24 days) had received an average of 3.5 transfusions before their enrollment. During the study, packed red blood cell transfusions were given according to criteria developed by the investigators.

Submitted on September 30, 1994
Accepted on September 30, 1994




This article has been cited by other articles:


Home page
 J. Nutr.Home page
J. A. Widness, R. E. Serfass, N. Haiden, S. E. Nelson, K. A. Lombard, and A. Pollak
Erythrocyte Iron Incorporation but Not Absorption Is Increased by Intravenous Iron Administration in Erythropoietin-Treated Premature Infants
J. Nutr., July 1, 2006; 136(7): 1868 - 1873.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. C. Lin, R. G. Strauss, J. C. Kulhavy, K. J. Johnson, M. B. Zimmerman, G. A. Cress, N. W. Connolly, and J. A. Widness
Phlebotomy Overdraw in the Neonatal Intensive Care Nursery
Pediatrics, August 1, 2000; 106(2): 19e - 19.
[Abstract] [Full Text]

Home page
 J. Appl. Physiol.Home page
J. A. Widness, L. S. Lowe, E. F. Bell, L. F. Burmeister, D. M. Mock, J. A. Kistard, and H. Bard
Adaptive responses during anemia and its correction in lambs
J Appl Physiol, April 1, 2000; 88(4): 1397 - 1406.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
K. M. Moritz, G. B. Lim, and E. M. Wintour
Developmental regulation of erythropoietin and erythropoiesis
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 1997; 273(6): R1829 - R1844.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
B. Meister, H. Maurer, B. Simma, H. Kern, H. Ulmer, A. Hittmair, and F.-M. Fink
The Effect of Recombinant Human Erythropoietin on Circulating Hematopoietic Progenitor Cells in Anemic Premature Infants
Stem Cells, September 1, 1997; 15(5): 359 - 363.
[Abstract] [Full Text]